IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
ImmunityBio, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $112.98M | $14.15M | $0 | $0 | – | – | – | – | – | – | 99.7% | +698.5% |
| Other revenues | $306.00K | $595.00K | $622.00K | $240.00K | – | – | – | – | – | – | 0.3% | -48.6% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $113.01M | $14.21M | $31.00K | $42.00K | $373.00K | $513.00K | $2.00M | $45.00K | $44.00K | $191.00K | 99.8% | +695.1% |
| Europe | $278.00K | $531.00K | $591.00K | $198.00K | $561.00K | $92.00K | $205.00K | $0 | $0 | $21.00K | 0.2% | -47.6% |
| Foreign Jurisdictions | – | – | – | – | – | – | – | $0 | $0 | $24.00K | – | – |
From the segment and revenue-disaggregation notes of ImmunityBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.